Endocrinology 

Help Shape the Future of Denosumab Treatment

As biosimilars enter the denosumab landscape, your perspective as a healthcare provider is critical in understanding what factors influence treatment decisions. This brief survey explores your views on reimbursement considerations, coding challenges, switching comfort, and drivers of biosimilar choice. As a thank you, by completing the survey, you’ll be entered into a drawing for a chance to win a $200 gift card.

Take the survey now and make your voice heard

Articles

Your daily dose of the clinical news you may have missed.

New Data Highlight Significant Challenges to Managing CAH: Daily Dose

A new analysis of the CAHtalog phase 3 study showed approximately 95% of participants experienced either high glucocorticoid exposure or elevated androstenedione levels during treatment.

ENDO 2025: Most Patients With Classic Congenital Adrenal Hyperplasia Experience High Glucocorticoid Exposure or Suboptimal Control

Slideshows

An oral antibiotic for drug-resistant UTIs, a long-awaited therapy for congenital adrenal hyperplasia, and more.

Adrenal Disorders